Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 6/20 | 0.49 |
| ▸ | FNTB | P49356 | 6/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13384296 | 0.96 | CYP1A2 (0.45) | FNTAFNTBKDM1ACYP1A2ACE2 | |
| SCHEMBL13384002 | 0.89 | KDM1A (0.51) | FNTAFNTBKDM1AACE2 | |
| SCHEMBL18879196 | 0.85 | KDM1A (0.43) | FNTAFNTBKDM1AKMT2A | |
| SCHEMBL31402629 | 0.83 | FNTA (0.46) | FNTAFNTBKDM1ACYP1A2KMT2A | |
| SCHEMBL13383944 | 0.83 | KDM1A (0.45) | FNTAFNTBKDM1ACYP1A2ACE2 | |
| SCHEMBL14137428 | 0.83 | KDM1A (0.41) | FNTAFNTBKDM1AKMT2A | |
| SCHEMBL13384219 | 0.82 | KDM1A (0.55) | FNTAFNTBKDM1AACE2 | |
| SCHEMBL9808075 | 0.82 | GABRR1 (0.43) | FNTAFNTBKDM1ACYP1A2ACE2 | |
| SCHEMBL9808071 | 0.82 | GABRR1 (0.43) | FNTAFNTBKDM1ACYP1A2ACE2 | |
| SCHEMBL13384294 | 0.81 | KDM1A (0.46) | FNTAFNTBKDM1ACYP1A2ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2682746-B1 | Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states | PHENOMENOME DISCOVERIES INC (CA) | 2017-05-24 | — | — | EP | disclosed |
| US-20160377623-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20160305928-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-10-20 | — | — | US | disclosed |
| US-20160305928-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | MED-LIFE DISCOVERIES LP (CA) | 2016-10-20 | — | — | US | disclosed |
| US-20100086960-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2010-04-08 | — | — | US | disclosed |
| US-20100086960-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2010-04-08 | — | — | US | disclosed |
| WO-2008092280-A1 | METHODS FOR THE DIAGNOSIS OF OVARIAN CANCER HEALTH STATES AND RISK OF OVARIAN CANCER HEALTH STATES | PHENOMENOME DISCOVERIES INC. (CA) | 2008-08-07 | — | — | WO | disclosed |